Sotorasib in <i>KRAS</i> p.G12C–Mutated Advanced Pancreatic Cancer
2022 · New England Journal of Medicine · 425 citations
https://doi.org/10.1056/nejmoa2208470
H
Hironaga Satake
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
302
Papers
3.5K
Citations
24
h-index
53
i10-index
Hironaga Satake is an academic researcher from Kochi Medical School Hospital. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Gastric Cancer Management and Outcomes & Cancer Treatment and Pharmacology. The author has an h-index of 24, co-authored 257 publications.
ORCID: 0000-0001-7629-6803Papers by this author
worksTargeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
2024 · Nature Medicine · 42 citations
https://doi.org/10.1038/s41591-024-03244-8
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B
2019 · Cancer Chemotherapy and Pharmacology · 27 citations
https://doi.org/10.1007/s00280-019-03991-3
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
2017 · Gastric Cancer · 26 citations
https://doi.org/10.1007/s10120-017-0766-x
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
2020 · BMC Cancer · 19 citations
https://doi.org/10.1186/s12885-020-07186-5
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
2022 · ESMO Open · 18 citations
https://doi.org/10.1016/j.esmoop.2022.100512
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat